Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2

Oncotarget

Volumn 7, Issue 8, 2016, Pages 8866-8878

  Xu, Yaping ^a,b   Zhao, Wenxiu ^a   Xu, Jianfeng ^a   Li, Jie ^a   Hong, Zaifa ^a   Yin, Zhenyu ^a   Wang, Xiaomin ^a  

^a ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b Xiamen Medical College   (China)

Author keywords

Cyclooxygenase 2; Hepatic stellate cell; Hepatocellular carcinoma; Myeloid derived suppressor cells; Prostaglandin 2

Indexed keywords

ARGINASE 1; B7 ANTIGEN; CD86 ANTIGEN; CYCLOOXYGENASE 2; GLYCOPROTEIN P 15095; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 4 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; PROSTAGLANDIN E2; CYCLOOXYGENASE 2 INHIBITOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BONE MARROW CELL; CANCER GROWTH; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; ENZYME INHIBITION; FLOW CYTOMETRY; IN VITRO STUDY; INCUBATION TIME; INTRACELLULAR SIGNALING; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOLECULAR DYNAMICS; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN EXPRESSION; STELLATE CELL; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEPATIC STELLATE CELL; LIVER TUMOR; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; BONE MARROW; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FLOW CYTOMETRY; HEPATIC STELLATE CELLS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MYELOID-DERIVED SUPPRESSOR CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84961615997     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6839     Document Type: Article

References (60)

1. Thun MJ, DeLancey JO, Center MM, Jemal A and Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31:100-110
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917
3. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612
4. Puche JE, Saiman Y and Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013; 3:1473-1492
5. Lee YS and Jeong WI. Retinoic acids and hepatic stellate cells in liver disease. J Gastroenterol Hepatol. 2012; 27 Suppl 2:75-79
6. Yu MC, Chen CH, Liang X, Wang L, Gandhi CR, Fung JJ, Lu L and Qian S. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology. 2004; 40:1312-1321
7. Chou H-S, Hsieh C-C, Yang H-R, Wang L, Arakawa Y, Brown K, Wu Q, Lin F, Peters M, Fung JJ, Lu L and Qian S. Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology. 2011; 53:1007-1019
8. Sun Y, Xi D, Ding W, Wang F, Zhou H and Ning Q. Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma. Hepatol Int. 2014; 8:567-575
9. Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, You J, Fan J and Wang X. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer. 2011; 129:2651-2661
10. Zhao W, Zhang L, Xu Y, Zhang Z, Ren G, Tang K, Kuang P, Zhao B, Yin Z and Wang X. Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Invest. 2014; 94:182-191
11. Gabrilovich DI and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9:162-174
12. Kohanbash G and Okada H. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol Invest. 2012; 41:658-679
13. Youn JI, Nagaraj S, Collazo M and Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008; 181:5791-5802
14. Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, Mastorodemos V, Plaitakis A, Sharpe A, Boumpas D and Verginis P. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol. 2012; 188:1136-1146
15. Hochst B, Schildberg FA, Sauerborn P, Gabel YA, Gevensleben H, Goltz D, Heukamp LC, Turler A, Ballmaier M, Gieseke F, Muller I, Kalff J, Kurts C, et al. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J Hepatol. 2013; 59:528-535
16. Hsieh CC, Chou HS, Yang HR, Lin F, Bhatt S, Qin J, Wang L, Fung JJ, Qian S and Lu L. The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood. 2013; 121:1760-1768
17. Chen CH, Kuo LM, Chang Y, Wu W, Goldbach C, Ross MA, Stolz DB, Chen L, Fung JJ, Lu L and Qian S. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology. 2006; 44:1171-1181
18. Sugimoto Y and Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007; 282:11613-11617
19. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012; 188:21-28
20. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP and Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011; 118:5498-5505
21. Obermajer N and Kalinski P. Generation of myeloidderived suppressor cells using prostaglandin E2. Transplant Res. 2012; 1:15
22. Cardoso CC, Paviani ER, Cruz LA, Guma FC, Borojevic R and Guaragna RM. Effect of pentoxifylline on arachidonic acid metabolism, neutral lipid synthesis and accumulation during induction of the lipocyte phenotype by retinol in murine hepatic stellate cell. Mol Cell Biochem. 2003; 254:37-46
23. Olaso E, Salado C, Egilegor E, Gutierrez V, Santisteban A, Sancho-Bru P, Friedman SL and Vidal-Vanaclocha F. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology. 2003; 37:674-685
24. Hui AY, Dannenberg AJ, Sung JJ, Subbaramaiah K, Du B, Olinga P and Friedman SL. Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells. J Hepatol. 2004; 41:251-258
25. Condamine T and Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011; 32:19-25
26. Sumida K, Wakita D, Narita Y, Masuko K, Terada S, Watanabe K, Satoh T, Kitamura H and Nishimura T. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol. 2012; 42:2060-2072
27. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH and Chen MF. Significance of IL-6 in the transition of hormoneresistant prostate cancer and the induction of myeloidderived suppressor cells. J Mol Med (Berl). 2012; 90:1343-1355
28. Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM and Chen SH. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008; 111:219-228
29. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP and Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011; 71:7463-7470
30. Sinha P, Clements VK, Fulton AM and Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007; 67:4507-4513
31. Zhao W, Su W Fau-Kuang P, Kuang P Fau-Zhang L, Zhang L Fau-Liu J, Liu J Fau-Yin Z, Yin Z Fau-Wang X and Wang X. The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma. Int J Oncol. 2012;41:457-64
32. Rabinovich GA, Gabrilovich D and Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25:267-296
33. Bunt SK, Yang L, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloidderived suppressor cells and limits tumor progression. Cancer Res. 2007; 67:10019-10026
34. Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis. 2001; 21:417-426
35. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V and Borrello I. High-dose granulocyte-macrophage colonystimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004; 64:6337-6343
36. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S and Carbone DP. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998; 92:4150-4166
37. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM and Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005; 65:9525-9535
38. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Muller M, Blander JM, Tacke F and Trautwein C. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010; 207:1453-1464
39. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S and Bronte V. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity. 2010; 32:790-802
40. Lechner MG, Liebertz DJ and Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010; 185:2273-2284
41. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J and Ochoa AC. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005; 202:931-939
42. Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, Cheng Z, Shah SV, Wang GJ, Zhang L, Grizzle WE, Mobley J and Zhang HG. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009; 124:2621-2633
43. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim JC, Gulen D, Bishay J and Talmadge JE. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol. 2009; 9:937-948
44. Cheng J, Imanishi H, Liu W, Iwasaki A, Ueki N, Nakamura H and Hada T. Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398. Biochem Biophys Res Commun. 2002; 297:1128-1134
45. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 1999; 29:688-696
46. Mallat A, Gallois C, Tao J, Habib A, Maclouf J, Mavier P, Preaux AM and Lotersztajn S. Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J Biol Chem. 1998; 273:27300-27305
47. Failli P, De FR, Caligiuri A, Gentilini A, Romanelli RG, Marra F, Batignani G, Guerra CT, Laffi G, Gentilini P and Pinzani M. Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology. 2000; 119:479-492
48. Efsen E, Bonacchi A, Pastacaldi S, Valente AJ, Wenzel UO, Tosti-Guerra C, Pinzani M, Laffi G, Abboud HE, Gentilini P and Marra F. Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. Hepatology. 2001; 33:713-721
49. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R and Lundqvist A. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 2014; 20:4096-4106
50. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR and Okada H. COX-2 blockade suppresses gliomagenesis by inhibiting myeloidderived suppressor cells. Cancer Res. 2011; 71:2664-2674
51. Serafini P. Editorial: PGE2-producing MDSC: a role in tumor progression? J Leukoc Biol. 2010; 88:827-829
52. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG and Hegmans JP. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010; 10:464
53. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K and Kalinski P. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest. 2012; 41:635-657
54. Zhang Y, Liu Q, Zhang M, Yu Y, Liu X and Cao X. Fas signal promotes lung cancer growth by recruiting myeloidderived suppressor cells via cancer cell-derived PGE2. J Immunol. 2009; 182:3801-3808
55. Yao C, Hirata T, Soontrapa K, Ma X, Takemori H and Narumiya S. Prostaglandin E(2) promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase. Nat Commun. 2013; 4:1685
56. Candelario-Jalil E, Slawik H, Ridelis I, Waschbisch A, Akundi RS, Hull M and Fiebich BL. Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in Purkinje cells of the cerebellum. J Mol Neurosci. 2005; 27:303-310
57. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X and Wang Q. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol. 2012; 188:5500-5510
58. Youn J-I, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013; 14:211-220
59. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5:263-274
60. Chun E, Lavoie S, Michaud M, Gallini CA, Kim J, Soucy G, Odze R, Glickman JN and Garrett WS. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. Cell Rep. 2015; 12:244-257